Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulenistamab - Prestige BioPharma

Next Previous
Drug Profile

Ulenistamab - Prestige BioPharma

Alternative Names: Anti-PAUF antibody - Prestige Biopharma; PBP-1510

Latest Information Update: 21 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prestige BioPharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action PAUF protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 31 May 2024 Adverse events data from a phase I/IIa trial in Pancreatic cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 27 May 2024 Phase-I/II clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in Singapore (IV) prior to May 2024 (NCT05141149) (EudraCT2021-000682-32)
  • 22 Mar 2023 Ulenistamab receives Fast Track designation for Pancreatic cancer [IV,Infusion] (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top